EUVIMEDEUVIMED entdecken
Fallbericht

Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience

Gonul Buyukyilmaz iD, Mehmet Adiguzel iD, Fatih Gurbuz iD, Esra Kılıc iD

American Journal of Medical Genetics Part A · 2025

DOI: 10.1002/ajmg.a.63985 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Gonul Buyukyilmaz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Ankara Bilkent City Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Hajdu-Cheney Syndrome, Zoledronic Acid, Receptor, Notch2, Osteoporosis. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hajdu–Cheney syndrome (HCS), caused by a heterozygous gain of function variant of the NOTCH2 gene, is a rare skeletal dysplasia. Although the main presentation is acro‐osteolysis, osteoporosis, and facial dysmorphism, having a wide range of clinical manifestations creates diagnostic difficulties. Here, a 15‐year‐old male patient with HCS who had no complaints until this age except for two short bone fractures and one vertebral collapse fracture due to a fall was reported. The patient presented with acro‐osteolysis, facial anomalies, skull deformity, and osteoporosis. The clinical diagnosis of HCS was supported by a positive genetic test of a novel de novo heterozygous pathogenic variant in exon 34 of NOTCH2 c.6614dupAfs*. Zoledronic acid treatment was applied for 2 years, and the patient responded well to the treatment, showing signs of improved bone density and improvement in vertebral height. We identified a novel NOTCH2 gene variant related to HCS. Our findings could extend phenotypic spectrum and genotype–phenotype correlations. The results of this case report support that antiresorptive treatment with zoledronic acid increased bone mineral density. Nevertheless, because of the low prevalence of the syndrome and the small number of reported cases, further studies are required to understand the syndrome better and establish treatment guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hajdu-Cheney SyndromeZoledronic AcidReceptor, Notch2OsteoporosisAcro-OsteolysisHumansMaleAdolescentBone Density Conservation AgentsGenetic Association StudiesPhenotypeBone Density

Stichwörter der Autor:innen

NOTCH2Hajdu–Cheney syndromeacro‐osteolysisosteoporosiszoledronic acid

Substanzen

Zoledronic AcidReceptor, Notch2NOTCH2 protein, humanBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Pediatric Endocrinology, Ankara Bilkent City Hospital, Ankara, Turkey.
  • Department of Radiology, Dr. Burhan Nalbantoğlu State Hospital, Nicosia, Cyprus.
  • Department of Pediatric Endocrinology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.
  • Department of Pediatric Genetics, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

ORCID-Profile: Gonul Buyukyilmaz, Mehmet Adiguzel, Fatih Gurbuz, Esra Kılıc

Zitieren

APA

Buyukyilmaz, G., Adiguzel, M., Gurbuz, F., & Kılıc, E. (2025). Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63985

Vancouver

Buyukyilmaz G, Adiguzel M, Gurbuz F, Kılıc E. Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63985

BibTeX
@article{Buyukyilmaz2025,
  author = {Buyukyilmaz, Gonul and Adiguzel, Mehmet and Gurbuz, Fatih and Kılıc, Esra},
  title = {Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience},
  journal = {American Journal of Medical Genetics Part A},
  year = {2025},
  doi = {10.1002/ajmg.a.63985}
}
Kostenlos starten →